NCT03522064View on ClinicalTrials.gov

Bipolar Androgen Therapy + Carboplatin in mCRPC

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 30, 2018

Primary Completion Date

September 30, 2025

Study Completion Date

December 30, 2025

Conditions
Castration-resistant Prostate CancerHomologous Recombination Deficiency
Interventions
DRUG

Testosterone Enanthate 100 MG/ML Injectable Solution

Testosterone Enanthate is the oil-soluble ester of the androgenic hormone testosterone. Testosterone Enanthate is a clear to pale yellow solution for intramuscular injection. Each pre-filled syringe contains 250mg testosterone enanthate/1mL.

DRUG

Testosterone Enanthate 100 MG/ML Injectable Solution / Carboplatin AUC 5

Testosterone Enanthate is the oil-soluble ester of the androgenic hormone testosterone. Testosterone Enanthate is a clear to pale yellow solution for intramuscular injection. Each pre-filled syringe contains 250mg testosterone enanthate/1mL. Carboplatin as per standard procedures

Trial Locations (1)

2010

RECRUITING

Kinghorn Cancer Centre, St. Vincent's Hospital, Sydney

All Listed Sponsors
lead

St Vincent's Hospital, Sydney

OTHER